RecruitingNCT07160946

Risk Assessment for HBV-Related Liver Cancer

Research on Risk Assessment and Intervention of HBV-Related Liver Cancer Based on Multimodal Data Fusion


Sponsor

Sun Yat-sen University

Enrollment

6,000 participants

Start Date

May 10, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.


Eligibility

Min Age: 30 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for people with hepatitis B (a liver infection) who may be at higher risk of developing liver cancer, in order to improve how doctors predict and monitor that risk. **You may be eligible if...** - You test positive for the hepatitis B surface antigen (meaning you carry the hepatitis B virus) - AND at least one of the following applies: your scans show signs of liver scarring (cirrhosis); you have type 2 diabetes; you have a family history of liver cirrhosis or liver cancer; you have drunk heavily for more than 5 years; your liver biopsy shows significant scarring; or your liver stiffness score is high **You may NOT be eligible if...** - You have already been diagnosed with cancer - You have had a liver transplant - You are HIV positive - Your life expectancy is less than 1 year - You have serious organ problems (heart, kidneys, lungs, etc.) or a serious psychiatric condition Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAI folow-up system

In AI follow-up group, patients will be followed up by an AI system.


Locations(1)

Third Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07160946


Related Trials